Twin Focus Capital Partners’s Adverum Biotechnologies ADVM Stock Holding History

Twin Focus Capital Partners’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$95K	–	222
2022 Q3	$95K	Hold	10,000	–	–	0.02%	194
2022 Q2	$120K	Hold	10,000	–	–	0.03%	198
2022 Q1	$131K	Hold	10,000	–	–	0.03%	222
2021 Q4	$176K	Hold	10,000	–	–	0.04%	220
2021 Q3	$217K	Hold	10,000	–	–	0.05%	168
2021 Q2	$350K	Hold	10,000	–	–	0.08%	125
2021 Q1	$986K	Buy	+10,000	New	+$1.2M	0.28%	56

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Twin Focus Capital Partners's ADVM Position: Q4 2022 in Review

Twin Focus Capital Partners sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 10,000 shares — an estimated $95K sold.

Twin Focus Capital Partners first reported a position in ADVM in Q1 2021 and held it in 7 quarters. The position peaked at $986K in Q1 2021. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

Twin Focus Capital Partners reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
Twin Focus Capital Partners sold 10,000 Adverum Biotechnologies shares in Q4 2022, an estimated $95K.
Twin Focus Capital Partners first reported a position in Adverum Biotechnologies in Q1 2021 and held it in 7 quarters.
Twin Focus Capital Partners's Adverum Biotechnologies position peaked at $986K in Q1 2021.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on Twin Focus Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.